Accuracy of ESAT6-CFP10 skin test compared with tuberculin skin test in a healthy population: a randomized, blind, parallel controlled phase III clinical study
Abstract Background This study aimed to evaluate the diagnostic performance of ESAT6-CFP10 (EC) skin test in healthy population and determine the factors influencing the booster effect. Methods We conducted a randomized, double-blind, parallel controlled trial in healthy population. The experiment w...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-12-01
|
| Series: | BMC Infectious Diseases |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12879-024-10302-6 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841559785727590400 |
|---|---|
| author | Xiaoyan Ding Weixin Du Qiao Liu Lifeng Tao Yan Shao Peng Lu Huaiyu Yang Xiaoxue Teng Cheng Chen Zhongqi Li Jinbiao Lu Aihua Zhao Guozhi Wang Miao Xu Limei Zhu |
| author_facet | Xiaoyan Ding Weixin Du Qiao Liu Lifeng Tao Yan Shao Peng Lu Huaiyu Yang Xiaoxue Teng Cheng Chen Zhongqi Li Jinbiao Lu Aihua Zhao Guozhi Wang Miao Xu Limei Zhu |
| author_sort | Xiaoyan Ding |
| collection | DOAJ |
| description | Abstract Background This study aimed to evaluate the diagnostic performance of ESAT6-CFP10 (EC) skin test in healthy population and determine the factors influencing the booster effect. Methods We conducted a randomized, double-blind, parallel controlled trial in healthy population. The experiment was divided into two stages. In the first stage, all participants underwent T-SPOT, TB-PPD, and EC tests. In the second stage, to evaluate whether BCG vaccination affected the efficacy of skin tests, the participants with three negative results in the first stage were randomly assigned to the BCG and placebo groups at a ratio of 2:1 and underwent three tests. The positivity rates and concordance of the three tests were calculated in both stages, and a logistic regression model was constructed to determine the factors influencing the booster effect of EC in the second stage. Safety observations were continued until the skin test results were available. Results In the first stage, 1,564 participants were enrolled in the study. The positivity rates of the T-SPOT, EC, and TB-PPD tests in all the participants were 18.89%, 10.37%, and 53.96%, respectively. The concordance between the EC and T-SPOT tests was 88.97% (kappa = 0.56), and that between the TB-PPD and T-SPOT tests was 58.19% (kappa = 0.20). In the second stage, 585 participants were assigned to the BCG or placebo group. In the BCG group, the positivity rates for the T-SPOT, EC, and TB-PPD tests were 4.76%, 7.30%, and 73.65%, respectively. The concordance between the EC and T-SPOT tests was 94.92% (kappa = 0.55), and that between the TB-PPD and T-SPOT tests was 29.84% (kappa = 0.02). In the placebo group, the positivity rates for the T-SPOT, EC, and TB-PPD tests were 6.88%, 11.88%, and 39.38%, respectively. The concordance between the EC and T-SPOT tests was 91.25% (kappa = 0.49), and that between the TB-PPD and T-SPOT tests was 66.25% (kappa = 0.17). The logistic regression model showed that age ≥ 60 years (odds ratio [OR] = 5.42, 95% confidence interval [CI]: 2.05–14.26) and retest positivity of T-SPOT test (OR = 44.87, 95% CI: 16.58–135.21) were stimulative factors of EC booster effect. Adverse reactions occurred in 168 (10.74%) and 33 participants (5.64%) in the first and second stage, respectively. Most of these were local adverse reactions, including injection site pain, pruritus, and rash. Conclusions The diagnostic performance of the EC skin test was similar to that of the T-SPOT test in the healthy population and was unaffected by BCG vaccination. The booster effects were more inclined to occur in population with retest positivity of T-SPOT or age ≥ 60 years. Clinical trials Registration NCT02795260, Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 on Healthy People Aged 18–65(III-healthy), Registration Date: June 10, 2016. |
| format | Article |
| id | doaj-art-101ac547bee64a69a0114b3baef49dc7 |
| institution | Kabale University |
| issn | 1471-2334 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Infectious Diseases |
| spelling | doaj-art-101ac547bee64a69a0114b3baef49dc72025-01-05T12:09:55ZengBMCBMC Infectious Diseases1471-23342024-12-012411910.1186/s12879-024-10302-6Accuracy of ESAT6-CFP10 skin test compared with tuberculin skin test in a healthy population: a randomized, blind, parallel controlled phase III clinical studyXiaoyan Ding0Weixin Du1Qiao Liu2Lifeng Tao3Yan Shao4Peng Lu5Huaiyu Yang6Xiaoxue Teng7Cheng Chen8Zhongqi Li9Jinbiao Lu10Aihua Zhao11Guozhi Wang12Miao Xu13Limei Zhu14Jiangsu Provincial Center for Disease Control and PreventionNational Institutes for Food and Drug ControlJiangsu Provincial Center for Disease Control and PreventionAnhui Zhifei Longcom Biopharmaceutical Co., LtdJiangsu Provincial Center for Disease Control and PreventionJiangsu Provincial Center for Disease Control and PreventionAnhui Zhifei Longcom Biopharmaceutical Co., LtdAnhui Zhifei Longcom Biopharmaceutical Co., LtdJiangsu Provincial Center for Disease Control and PreventionJiangsu Provincial Center for Disease Control and PreventionNational Institutes for Food and Drug ControlNational Institutes for Food and Drug ControlNational Institutes for Food and Drug ControlNational Institutes for Food and Drug ControlJiangsu Provincial Center for Disease Control and PreventionAbstract Background This study aimed to evaluate the diagnostic performance of ESAT6-CFP10 (EC) skin test in healthy population and determine the factors influencing the booster effect. Methods We conducted a randomized, double-blind, parallel controlled trial in healthy population. The experiment was divided into two stages. In the first stage, all participants underwent T-SPOT, TB-PPD, and EC tests. In the second stage, to evaluate whether BCG vaccination affected the efficacy of skin tests, the participants with three negative results in the first stage were randomly assigned to the BCG and placebo groups at a ratio of 2:1 and underwent three tests. The positivity rates and concordance of the three tests were calculated in both stages, and a logistic regression model was constructed to determine the factors influencing the booster effect of EC in the second stage. Safety observations were continued until the skin test results were available. Results In the first stage, 1,564 participants were enrolled in the study. The positivity rates of the T-SPOT, EC, and TB-PPD tests in all the participants were 18.89%, 10.37%, and 53.96%, respectively. The concordance between the EC and T-SPOT tests was 88.97% (kappa = 0.56), and that between the TB-PPD and T-SPOT tests was 58.19% (kappa = 0.20). In the second stage, 585 participants were assigned to the BCG or placebo group. In the BCG group, the positivity rates for the T-SPOT, EC, and TB-PPD tests were 4.76%, 7.30%, and 73.65%, respectively. The concordance between the EC and T-SPOT tests was 94.92% (kappa = 0.55), and that between the TB-PPD and T-SPOT tests was 29.84% (kappa = 0.02). In the placebo group, the positivity rates for the T-SPOT, EC, and TB-PPD tests were 6.88%, 11.88%, and 39.38%, respectively. The concordance between the EC and T-SPOT tests was 91.25% (kappa = 0.49), and that between the TB-PPD and T-SPOT tests was 66.25% (kappa = 0.17). The logistic regression model showed that age ≥ 60 years (odds ratio [OR] = 5.42, 95% confidence interval [CI]: 2.05–14.26) and retest positivity of T-SPOT test (OR = 44.87, 95% CI: 16.58–135.21) were stimulative factors of EC booster effect. Adverse reactions occurred in 168 (10.74%) and 33 participants (5.64%) in the first and second stage, respectively. Most of these were local adverse reactions, including injection site pain, pruritus, and rash. Conclusions The diagnostic performance of the EC skin test was similar to that of the T-SPOT test in the healthy population and was unaffected by BCG vaccination. The booster effects were more inclined to occur in population with retest positivity of T-SPOT or age ≥ 60 years. Clinical trials Registration NCT02795260, Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 on Healthy People Aged 18–65(III-healthy), Registration Date: June 10, 2016.https://doi.org/10.1186/s12879-024-10302-6TuberculosisESAT6-CFP10InfectionDiagnostics |
| spellingShingle | Xiaoyan Ding Weixin Du Qiao Liu Lifeng Tao Yan Shao Peng Lu Huaiyu Yang Xiaoxue Teng Cheng Chen Zhongqi Li Jinbiao Lu Aihua Zhao Guozhi Wang Miao Xu Limei Zhu Accuracy of ESAT6-CFP10 skin test compared with tuberculin skin test in a healthy population: a randomized, blind, parallel controlled phase III clinical study BMC Infectious Diseases Tuberculosis ESAT6-CFP10 Infection Diagnostics |
| title | Accuracy of ESAT6-CFP10 skin test compared with tuberculin skin test in a healthy population: a randomized, blind, parallel controlled phase III clinical study |
| title_full | Accuracy of ESAT6-CFP10 skin test compared with tuberculin skin test in a healthy population: a randomized, blind, parallel controlled phase III clinical study |
| title_fullStr | Accuracy of ESAT6-CFP10 skin test compared with tuberculin skin test in a healthy population: a randomized, blind, parallel controlled phase III clinical study |
| title_full_unstemmed | Accuracy of ESAT6-CFP10 skin test compared with tuberculin skin test in a healthy population: a randomized, blind, parallel controlled phase III clinical study |
| title_short | Accuracy of ESAT6-CFP10 skin test compared with tuberculin skin test in a healthy population: a randomized, blind, parallel controlled phase III clinical study |
| title_sort | accuracy of esat6 cfp10 skin test compared with tuberculin skin test in a healthy population a randomized blind parallel controlled phase iii clinical study |
| topic | Tuberculosis ESAT6-CFP10 Infection Diagnostics |
| url | https://doi.org/10.1186/s12879-024-10302-6 |
| work_keys_str_mv | AT xiaoyanding accuracyofesat6cfp10skintestcomparedwithtuberculinskintestinahealthypopulationarandomizedblindparallelcontrolledphaseiiiclinicalstudy AT weixindu accuracyofesat6cfp10skintestcomparedwithtuberculinskintestinahealthypopulationarandomizedblindparallelcontrolledphaseiiiclinicalstudy AT qiaoliu accuracyofesat6cfp10skintestcomparedwithtuberculinskintestinahealthypopulationarandomizedblindparallelcontrolledphaseiiiclinicalstudy AT lifengtao accuracyofesat6cfp10skintestcomparedwithtuberculinskintestinahealthypopulationarandomizedblindparallelcontrolledphaseiiiclinicalstudy AT yanshao accuracyofesat6cfp10skintestcomparedwithtuberculinskintestinahealthypopulationarandomizedblindparallelcontrolledphaseiiiclinicalstudy AT penglu accuracyofesat6cfp10skintestcomparedwithtuberculinskintestinahealthypopulationarandomizedblindparallelcontrolledphaseiiiclinicalstudy AT huaiyuyang accuracyofesat6cfp10skintestcomparedwithtuberculinskintestinahealthypopulationarandomizedblindparallelcontrolledphaseiiiclinicalstudy AT xiaoxueteng accuracyofesat6cfp10skintestcomparedwithtuberculinskintestinahealthypopulationarandomizedblindparallelcontrolledphaseiiiclinicalstudy AT chengchen accuracyofesat6cfp10skintestcomparedwithtuberculinskintestinahealthypopulationarandomizedblindparallelcontrolledphaseiiiclinicalstudy AT zhongqili accuracyofesat6cfp10skintestcomparedwithtuberculinskintestinahealthypopulationarandomizedblindparallelcontrolledphaseiiiclinicalstudy AT jinbiaolu accuracyofesat6cfp10skintestcomparedwithtuberculinskintestinahealthypopulationarandomizedblindparallelcontrolledphaseiiiclinicalstudy AT aihuazhao accuracyofesat6cfp10skintestcomparedwithtuberculinskintestinahealthypopulationarandomizedblindparallelcontrolledphaseiiiclinicalstudy AT guozhiwang accuracyofesat6cfp10skintestcomparedwithtuberculinskintestinahealthypopulationarandomizedblindparallelcontrolledphaseiiiclinicalstudy AT miaoxu accuracyofesat6cfp10skintestcomparedwithtuberculinskintestinahealthypopulationarandomizedblindparallelcontrolledphaseiiiclinicalstudy AT limeizhu accuracyofesat6cfp10skintestcomparedwithtuberculinskintestinahealthypopulationarandomizedblindparallelcontrolledphaseiiiclinicalstudy |